The number of patients taking immunosuppressive drugs for the management of autoimmune inflammatory conditions is increasing. The general practitioner needs to be active in preventing, monitoring and managing the adverse effects of these drugs even long after the treatment has ceased. monitoring is required because immunosuppressive drugs increase the risks of infection, malignancy, cardiovascular disease and bone marrow suppression. Some drugs have additional risks which require specific monitoring. Vigilance is needed as adverse effects may have atypical clinical presentations.
Introduction
General practitioners are increasingly likely to encounter patients who are taking immunosuppressive drugs for disease control in a variety of autoimmune inflammatory conditions. These include rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease and systemic vasculitis. The drugs are also used in transplantation. Although these drugs are usually started by specialists, general practitioners need to be aware of the long-term adverse effects so that there is no delay in detecting problems.
General risks of immunosuppressive drugs
Drugs which suppress the immune system are inevitably associated with increased risk of infection and malignancy.
Many of these drugs also impact adversely on patients' cardiovascular risk.
Infections
Patients may be infected by common community-acquired and 
Marrow suppression and cytopenia
Bone marrow suppression is a common dose-limiting toxicity for most immunosuppressive drugs, apart from hydroxychloroquine and the glucocorticoids. The recommendations for monitoring are largely based on expert consensus and often differ slightly. 1, 2 Table 1 
Specific long-term toxicities requiring monitoring
In addition to their general effects on the immune system, immunosuppressant therapies have drug interactions (see box) and adverse effects. Monitoring aims to detect these problems early.
Glucocorticoids
Corticosteroids are commonly used immunosuppressive drugs. 
Bone protection
Glucocorticoids alter bone metabolism. They reduce bone formation and increase resorption leading to substantial decreases in bone mineral density, especially in the first few months of use, and to increased fracture rates. Baseline bone mineral density should be measured if corticosteroid therapy is likely to be required for more than three months. Boneprotective therapy should be commenced at the time of starting corticosteroids in high-risk individuals, for example those aged 65 years or over, those with prior fragility fracture and those who are osteopenic. 3 There is evidence for the use of adequate doses of calcium and vitamin D with bisphosphonates for the prevention or reduction of steroid-induced bone loss and fracture. 4 
Some important interactions with immunosuppressive drugs

Cardiovascular risk
A large cohort study has shown that even after adjustment for known covariates, the relative risk for cardiovascular events in patients receiving high-dose glucocorticoids was 2.56. 5 The risks of individual outcomes such as death, heart failure, myocardial infarction, stroke and transient ischaemic attacks are all significantly higher for those prescribed high-dose glucocorticoids. Tight control of cardiovascular risk factors is therefore essential for those taking corticosteroids.
Eyes
Glucocorticoids cause cataract formation and can increase intraocular pressure. Currently, there is no recommendation for regular ophthalmological review, however enquiry about eye symptoms and yearly optometry review with measurement of intraocular pressure is prudent.
Hydroxychloroquine
This antimalarial drug has immunomodulatory properties and is used in a variety of autoimmune diseases. It is relatively well tolerated at the commonly used dosages of 200-400 mg/day.
Retinopathy has been well documented with doses greater than 6.5 mg/kg/day (a dose rarely used today). Hydroxychloroquine is contraindicated in patients with pre-existing maculopathy.
Guidelines regarding the need for regular ophthalmological reviews vary. The American Academy of Ophthalmology recommends ophthalmological examination within the first year of treatment. If a patient is in the low-risk category (no liver disease, no retinal disease and age less than 60), no further ophthalmological testing is needed for the next five years.
Patients at high risk require annual examinations. 6 The usual practice in Australia is annual ophthalmological review.
Leflunomide
Elevation of liver enzymes is a common toxicity of leflunomide.
Three-fold elevations occur in up to 10% of patients, but these are generally reversible with dose reduction or discontinuation of the drug. Liver function tests should be done at regular intervals.
Blood pressure monitoring is required as a small percentage of patients become hypertensive. The risk is increased with concomitant use of non-steroidal anti-inflammatory drugs.
Methotrexate
Methotrexate is usually taken orally once a week on a nominated day, in combination with folic acid to reduce toxicity.
The general practitioner needs to take special care as toxicity from methotrexate can occur during long-term use, with up to 30% of patients treated for more than five years discontinuing due to unacceptable toxicity in some series.
An interaction with non-steroidal anti-inflammatory drugs can increase toxicity, but this is less likely to occur with low doses of methotrexate. Penicillins and sulfonamides reduce the excretion of methotrexate. As trimethoprim also increases the risk of toxicity, the combination of trimethoprim and sulfamethoxazole should generally be avoided in patients taking methotrexate.
Myelosuppression
Myelosuppression is the major dose-limiting adverse effect of methotrexate. It is particularly likely in the elderly and patients with renal impairment or concomitant administration of antifolate drugs such as cotrimoxazole and phenytoin. A full blood count every 1-3 months is advisable.
Hepatotoxicity
Hepatotoxicity occurs at a frequency of 1 per 35 patient years.
It is usually associated with a cumulative dose of at least 1.5 g.
Alcohol is a major risk factor and should be avoided. The 
Calcineurin inhibitors
The adverse effects and monitoring required for cyclosporin and tacrolimus are similar. The doses used in autoimmune disease are much lower than in transplantation so there is less toxicity, and regular monitoring of drug concentration is not mandatory.
Nephrotoxicity characterised by rising urea and creatinine is a 
Mycophenolate
The main toxicity of mycophenolate which requires monitoring is cytopenia. As mycophenolate is renally cleared, dose adjustment is necessary in renal impairment.
Conclusion
Immunosuppressive drugs are efficacious in inducing and maintaining remission in organ threatening inflammatory diseases, but are also associated with significant adverse effects and toxicity. Health professionals involved in the patient's management need to be vigilant and proactive in preventing, monitoring and managing adverse effects. This surveillance may need to continue long after the drugs have been stopped.
